Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
Iovance Biotherapeutics Inc (NASDAQ: IOVA) closed the day trading at $2.21 up 0.91% from the previous closing price of $2.19. In other words, the price has increased by $0.91 from its previous closing price. On the day, 7.3 million shares were traded. IOVA stock price reached its highest trading level at $2.28 during the session, while it also had its lowest trading level at $2.15.
Ratios:
For a better understanding of IOVA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.89 and its Current Ratio is at 3.27. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.06.
On May 16, 2025, UBS Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $2.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 05 ’25 when Kirby Daniel Gordon bought 30,000 shares for $1.84 per share. The transaction valued at 55,200 led to the insider holds 30,000 shares of the business.
Puri Raj K. bought 5,600 shares of IOVA for $9,743 on May 23 ’25. The Chief Regulatory Officer now owns 206,852 shares after completing the transaction at $1.74 per share. On May 14 ’25, another insider, Vogt Frederick G, who serves as the Interim CEO & General Counsel of the company, bought 25,000 shares for $1.69 each. As a result, the insider paid 42,250 and bolstered with 374,646 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IOVA now has a Market Capitalization of 799697408 and an Enterprise Value of 551682112. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.31 while its Price-to-Book (P/B) ratio in mrq is 1.08. Its current Enterprise Value per Revenue stands at 2.284 whereas that against EBITDA is -1.466.
Stock Price History:
The Beta on a monthly basis for IOVA is 0.84, which has changed by -0.78871894 over the last 52 weeks, in comparison to a change of 0.1716845 over the same period for the S&P500. Over the past 52 weeks, IOVA has reached a high of $12.51, while it has fallen to a 52-week low of $1.64. The 50-Day Moving Average of the stock is -5.99%, while the 200-Day Moving Average is calculated to be -47.68%.
Shares Statistics:
Over the past 3-months, IOVA traded about 17.07M shares per day on average, while over the past 10 days, IOVA traded about 9798440 shares per day. A total of 341.92M shares are outstanding, with a floating share count of 292.73M. Insiders hold about 19.10% of the company’s shares, while institutions hold 53.65% stake in the company. Shares short for IOVA as of 1755216000 were 71364792 with a Short Ratio of 4.18, compared to 1752537600 on 98633209. Therefore, it implies a Short% of Shares Outstanding of 71364792 and a Short% of Float of 21.440001.
Earnings Estimates
As of right now, 9.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.18, with high estimates of -$0.12 and low estimates of -$0.25.
Analysts are recommending an EPS of between -$1.0 and -$1.25 for the fiscal current year, implying an average EPS of -$1.1. EPS for the following year is -$0.66, with 10.0 analysts recommending between -$0.42 and -$0.97.
Revenue Estimates
11 analysts predict $76.19M in revenue for the current quarter. It ranges from a high estimate of $84.2M to a low estimate of $70M. As of the current estimate, Iovance Biotherapeutics Inc’s year-ago sales were $58.55MFor the next quarter, 11 analysts are estimating revenue of $88.56M. There is a high estimate of $106.71M for the next quarter, whereas the lowest estimate is $75.88M.
A total of 11 analysts have provided revenue estimates for IOVA’s current fiscal year. The highest revenue estimate was $300M, while the lowest revenue estimate was $255.73M, resulting in an average revenue estimate of $275.57M. In the same quarter a year ago, actual revenue was $164.07MBased on 11 analysts’ estimates, the company’s revenue will be $436.22M in the next fiscal year. The high estimate is $540.4M and the low estimate is $350M.
